医疗科技公司Teleflex将于5月1日召开电话会议, 讨论第一季度的业绩, FDA的批准, 以及业务的分拆. Teleflex, a medical tech firm, hosts a call on May 1 to discuss Q1 results, FDA clearance, and a business split.

Teleflex公司是一家医疗技术公司,将于2025年5月1日东部时间上午8时举行电话会议,讨论第一季度的财务结果和业务最新情况。 Teleflex Incorporated, a medical tech company, will hold a conference call on May 1, 2025, at 8:00 am Eastern Time, to discuss its first quarter financial results and operational updates. 与会者可通过预先登记或通过网络直播参加。 Participants can join by pre-registering or through a live webcast. 该公司已经获得林业发展局对AC3 RangeTM IABP的许可,并正在提交RingerTM PBC研究的初步结果。 The company has received FDA clearance for its AC3 Range™ IABP and is presenting preliminary results of its Ringer™ PBC study. Teleflex还计划将两家公司分开,并收购BIOTRONIK的血管干预业务。 Teleflex also plans to separate into two companies and acquire BIOTRONIK's Vascular Intervention Business.